close initi outlook straddl street
reiter market outperform rate rais price
target follow morn releas result
new price target base unchang new ep
estim vs prior ep estim
wrap well deliv upsid top
bottom line initi guidanc look similar consensu
expect head quarter view constant currenc organ
sale growth coupl double-digit earn growth attract profil
mid-cap compani med-tech space target impli
anoth solid year
revenu mln y/i rpt cc organ line
cc organ growth post consensu mln
beat adjust ep y/i beat street
aid lower tax stem recent tax cut sale gain
primarili volum driven bp come price
initi guidanc call cc organ growth mln fx
benefit off-set impact divestitur impli sale rang
bln versu street bln adjust ep expect rang
y/i versu street reflect new
adjust tax rate versu prior
free cash flow expect approxim mln y/i capital-expenditure
mln manag note expect invest mln capital-expenditure
healthcar specialti servic outsourc spd steril process
depart effort ast appli steril technolog
mix standpoint versu street healthcar product
larg line life scienc ast deliv solid upsid
total backlog y/i mln healthcar product
y/i mln mln sequenti life scienc
mln mln sequenti balanc sheet cash
sit mln long-term debt bln ebitda
compani repatri mln cash primarili canada uk use
pay debt
healthcar product sale mln y/i rpt cc organ versu
consensu mln capit equip flat increas
servic flattish resutl consum limit divestitur oper
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
incom segment came mln y/i due higher spend
neg currenc higher alloc corpor cost
healthcar specialti servic sale mln y/i report cc
organ slightli consensu mln oper incom mln
significantli mln prior-year period primarili due continu improv
within im north america
ast sale mln y/i report cc organ versu consensu
mln driven primarili increas volum core medic devic custom oper incom
mln vs mln prior-year period increas driven larg
revenu growth fx chang
life scienc revenu mln y/i report cc organ versu
consensu mln servic sale grew capit equip increas
consum sale flat oper incom increas mln mln
prior-year period driven larg increas volum
gross margin grew bp y/i bp improv come
divestitur favor mix price contribut well currenc neg impact
bp gross margin ebit grew bp y/i somewhat limit growth
 spend hire rep north america higher opex includ bonus
manag offer initi guidanc call cc rpt top-lin growth ep
rang y/i midpoint street consensu sat midpoint
rang head releas
figur illustr actual vs jmp estim rang revenu metric along select
bpshealthcar spec bpslife bpsappli steril bpstotal mln annual bpsgross bpsup bp y/i due favor mix price bp divestitur off-set bp declin unfavor currenc impact sg includ bpsoper incom ex bpsroughli flat y/i limit expansio due increas spedn hire ramp na im busi higher corpor coststax bpsnet incom ex mix cc organ y/i consum servic capit equip flat capit equip backlog increas segment oper incom mln expect similar pace new product capit equip return normal growth mix y/i report basi reflectig final impact quarter divestitur linen busi currenc neutral organ growth oper incom segment mln primarili due improv within im na substanti invest segment grow outsourc reprocess mix currenc neutral organ growth quarter backlog increas capit equip segment consum flat servic revenu segment oper incom mix organ currenc neutral basi driven primarili increas volum segment core medic devic custom segment oper profit increas mln y/i due revenu growth chang currenc ri plc
steri corpor develop manufactur market infect prevent contamin control microbi reduct surgic
support product servic healthcar pharmaceut scientif research industri government custom world-wide
movement toward dispos surgic tool decreas need steril med-tech compani bring high-margin
single-us devic marketplac trend obvious reduc need steril surgic procedur
growth driver outsid may take longer expect materi capit spend may take longer rebound expect
tangibl sign capit equip market due rebound meaning delay could impact capit equip
sale estim compani
compani abil gener sustain earn dividend growth depend upon achiev mid-singl digit revenu growth
number factor impact includ limit price pressur macroeconomic-driven chang patient volum
chang capit purchas budget cycl
